Raquibul Hannan, M.D., Ph.D.

Chief of Genitourinary Radiation Oncology Service

Harold C. Simmons Comprehensive Cancer Center

Radiation Oncology
Radiation Therapy for Kidney Cancer
Radiation Therapy for Testicular Cancer

New Patient Appointment Accepting Virtual Visits or 214-645-8525

Biography

Raquibul Hannan, M.D., Ph.D., Professor and Chief of Genitourinary Radiation Oncology Service, became fascinated with cancer as an undergraduate at New York University. His curiosity led him to pursue a combined medical degree and Ph.D. at State University of New York at Brooklyn from 1999 to 2006. For his Ph.D. research he worked on the immunology of pancreatic carcinogenesis and discovered a novel marker for pancreatic cancer. Following a medical internship the next year, he completed his residency in radiation oncology at Montefiore Medical Center and Albert Einstein College of Medicine in 2011.

At UT Southwestern Medical Center, Dr. Hannan specializes in radiation treatment of genitourinary (GU) cancers including prostate, kidney, bladder, penile, testicular, and ureteral cancer.

Dr. Hannan is knowledgeable in a range of radiation techniques including IMRT, IGRT, linac-based SRS, SBRT, and intracavitary and interstitial brachytherapy.

As an expert in these areas as well as a leading young researcher on the topic of immunologic effects of radiation treatment and immunotherapy in general, he holds two international patents and has presented his findings at symposiums and conferences around the world.

Dr. Hannan is a member of a number of professional organizations including the American Society of Radiation Oncology (ASTRO), the American Board of Radiology (ABR), the American College of Radiology (ACR), the Radiological Society of North America (RSNA), and the American Society of Clinical Oncology (ASCO).

Meet Dr. Hannan

Dallas Radiation Oncologist

What if the body’s own immune system could fight off cancer? How does radiation treatment affect the patient’s immune response to cancer? These have been particular areas of interest and research for Dr. Raquibul Hannan. As a board-certified radiation oncologist and an expert in radiation therapy for patients with genitourinary cancer, he feels research into strategies for combining immunotherapy with radiation therapy is an effective means of maximizing the treatment outcome for his patients.

"One of the motivations I have in doing translational research is to improve my patients’ cancer outcome. I will go out of my way to make sure the patient is getting the right treatment and whatever is best for his or her outcome.”

Genitourinary cancers include prostate, kidney, bladder, penile, testicular, and ureteral cancer. External beam radiation, including intensity-modulated radiation therapy (IMRT), image-guided radiation therapy (IGRT), and stereotactic body radiation therapy (SBRT), typically plays a key role in the treatment of these cancers. As a scientist, Dr. Hannan is exploring strategies of combining immunotherapy with radiation therapy. As a physician, he will do whatever it takes to make sure a patient is getting the right treatment and achieving the best outcome possible.

State-of-the-art technology in radiation equipment and a cutting-edge scientific environment drew Dr. Hannan to UT Southwestern Medical Center. The latest technology makes a big difference in caring for patients, he says. “The better the technology, the more precise the delivery of radiation, which spares the normal structures and eradicates the tumor,” he says.

Education & Training

Residency - Montefiore Med. Ctr. & Albert Einstein College of Med. (2007-2011), Radiation Oncology
Internship - SUNY Downstate Medical Center (2006-2007), Internal Medicine
Medical School - SUNY Downstate Medical Center (2002-2006)
Graduate School - SUNY Downstate Medical Center (1999-2002)

Professional Associations & Affiliations

American Society of Therapeutic Radiology and Oncology
American Society of Clinical Oncology

Honors & Awards

International Patent 2005, Pancreatic Cancer-Associated Antigen, Antibody thereto, and Diagnostic and Treatment Methods
US Patent 2006, Pancreatic Cancer-Associated Antigen, Antibody thereto, and Diagnostic and Treatment Methods Development of a PaCa-Ag1-Specific Enzyme-Linked Immuno-Assay
Radiation and Cancer Biology Poster Award 2010, ASTRO 52nd Annual Meeting

Books & Publications

Publications
- Corrigendum to “Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostat Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial” [Eur. Eurol. 84(2) (2023) 156–163, (S0302283823027884), (10.1016/j.eururo.2023.04.024)]
  Sartor O, Karrison TG, Sandler HM, Gomella LG, Amin M, Purdy J, Michalski JM, Garzotto MG, Pervez N, Balogh AG, Rodrigues GB, Souhami L, Neil Reaume M, Williams SG, Hannan R, Jones CU, Horwitz EM, Rodgers JP, Feng FY, Rosenthal SA European urology 2024 Sep 86 289-290
- Performance deterioration of deep learning models after clinical deployment: a case study with auto-segmentation for definitive prostate cancer radiotherapy
  Wang B, Dohopolski M, Bai T, Wu J, Hannan R, Desai N, Garant A, Yang D, Nguyen D, Lin MH, Timmerman R, Wang X, Jiang SB Machine Learning: Science and Technology 2024 Jun 5
- Noninferiority of Hypofractionated vs Conventional Postprostatectomy Radiotherapy for Genitourinary and Gastrointestinal Symptoms: The NRG-GU003 Phase 3 Randomized Clinical Trial
  Buyyounouski MK, Pugh SL, Chen RC, Mann MJ, Kudchadker RJ, Konski AA, Mian OY, Michalski JM, Vigneault E, Valicenti RK, Barkati M, Lawton CA, Potters L, Monitto DC, Kittel JA, Schroeder TM, Hannan R, Duncan CE, Rodgers JP, Feng F, Sandler HM JAMA Oncology 2024 May 10 584-591
- Delphi consensus on stereotactic ablative radiotherapy for oligometastatic and oligoprogressive renal cell carcinoma—a European Society for Radiotherapy and Oncology study endorsed by the European Association of Urology
  Marvaso G, Jereczek-Fossa BA, Zaffaroni M, Vincini MG, Corrao G, Andratschke N, Balagamwala EH, Bedke J, Blanck O, Capitanio U, Correa RJ, De Meerleer G, Franzese C, Gaeta A, Gandini S, Garibaldi C, Gerszten PC, Gillessen S, Grubb WR, Guckenberger M, Hannan R, Jhaveri PM, Josipovic M, Kerkmeijer LG, Lehrer EJ, Lindskog M, Louie AV, Nguyen QN, Ost P, Palma DA, Procopio G, Rossi M, Staehler M, Tree AC, Tsang YM, Van As N, Zaorsky NG, Zilli T, Pasquier D, Siva S The Lancet Oncology 2024 May 25 e193-e204
- Targeted chemotherapy via HER2-based chimeric antigen receptor (CAR) engineered T-cell membrane coated polymeric nanoparticles
  Yaman S, Ramachandramoorthy H, Iyer P, Chintapula U, Nguyen T, Sabnani M, Kotadia T, Ghaffari S, Pop LM, Hannan R, Weidanz JA, Nguyen KT Bioactive Materials 2024 Apr 34 422-435
- Harnessing stereotactic precision in the fight against primary kidney cancer: time for a randomised trial?
  Yang DX, Hannan R The Lancet Oncology 2024 Mar 25 267-269
- Stereotactic Body Radiation Therapy for Primary Renal Cell Carcinoma: A Case-Based Radiosurgery Society Practice Guide
  Barbour AB, Upadhyay R, Anderson AC, Kutuk T, Kumar R, Wang SJ, Psutka SP, Fekrmandi F, Skalina KA, Bruynzeel AM, Correa RJ, Dal Pra A, Biancia CD, Hannan R, Louie A, Singh AK, Swaminath A, Tang C, Teh BS, Zaorsky NG, Lo SS, Siva S Practical Radiation Oncology 2024
- Stereotactic ablative radiotherapy for primary renal cell carcinoma
  Yang DX, Kwon YS, Timmerman R, Hannan R Clinical and Translational Radiation Oncology 2024 Jan 44
- Radiation-Induced Innate Neutrophil Response in Tumor Is Mediated by the CXCLs/CXCR2 Axis
  Zhang F, Mulvaney O, Salcedo E, Manna S, Zhu JZ, Wang T, Ahn C, Pop LM, Hannan R Cancers 2023 Dec 15
- Bony structure enhanced synthetic CT generation using Dixon sequences for pelvis MR-only radiotherapy
  Liang X, Yen A, Bai T, Godley A, Shen C, Wu J, Meng B, Lin MH, Medin P, Yan Y, Owrangi M, Desai N, Hannan R, Garant A, Jiang S, Deng J Medical physics 2023 Dec 50 7368-7382
- Role of primary and metastasis-directed stereotactic radiation therapy for advanced renal cell carcinoma
  Christensen M, Hannan R 2023 Nov 343-357
- Phase 2 Trial of Stereotactic Ablative Radiotherapy for Patients with Primary Renal Cancer
  Hannan R, McLaughlin MF, Pop LM, Pedrosa I, Kapur P, Garant A, Ahn C, Christie A, Zhu J, Wang T, Robles L, Durakoglugil D, Woldu S, Margulis V, Gahan J, Brugarolas J, Timmerman R, Cadeddu J European urology 2023 Sep 84 275-286
- Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostate Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial
  Sartor O, Karrison TG, Sandler HM, Gomella LG, Amin MB, Purdy J, Michalski JM, Garzotto MG, Pervez N, Balogh AG, Rodrigues GB, Souhami L, Reaume MN, Williams SG, Hannan R, Jones CU, Horwitz EM, Rodgers JP, Feng FY, Rosenthal SA European urology 2023 Aug 84 156-163
- Systemic immune parameters after prior radiation therapy in patients receiving immune checkpoint inhibitors
  Mundra V, Yang Y, von Itzstein MS, Fattah F, Gonugunta AS, Hannan R, Pop LM, Zhang Y, Wang Y, Sheffield T, Xie Y, Dowell JE, Homsi J, Rashdan S, Park J, Li Q, Wakeland EK, Gerber DE Translational Oncology 2023 Aug 34
- Life-threatening hemoptysis in patients with metastatic kidney cancer
  Patel VM, Elias R, Asokan A, Sharma A, Christie A, Pedrosa I, Chiu H, Reznik S, Hannan R, Timmerman R, Brugarolas J Clinical Genitourinary Cancer 2023 Aug 21 497-506
- Preliminary Evaluation of PTV Margins for Online Adaptive Radiation Therapy of the Prostatic Fossa
  Morgan HE, Wang K, Yan Y, Desai N, Hannan R, Chambers E, Cai B, Lin MH, Sher DJ, Wang J, Wang AZ, Jiang S, Timmerman R, Park C“, Garant A Practical Radiation Oncology 2023 Jul 13 e345-e353
- Review of Prospective Trials Assessing the Role of Stereotactic Body Radiation Therapy for Metastasis-directed Treatment in Oligometastatic Genitourinary Cancers
  Huynh MA, Tang C, Siva S, Berlin A, Hannan R, Warner A, Koontz B, De Meeleer G, Palma D, Ost P, Tran PT European Urology Oncology 2023 Feb 6 28-38
- Tumor loss-of-function mutations in STK11/LKB1 induce cachexia
  Iyengar P, Gandhi AY, Granados J, Guo T, Gupta A, Yu J, Llano EM, Zhang F, Gao A, Kandathil A, Williams D, Gao B, Girard L, Malladi V, Shelton JM, Evers BM, Hannan R, Ahn C, Minna JD, Infante RE JCI Insight 2023 8
- 5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney)
  Siva S, Ali M, Correa RJ, Muacevic A, Ponsky L, Ellis RJ, Lo SS, Onishi H, Swaminath A, McLaughlin M, Morgan SC, Cury FL, Teh BS, Mahadevan A, Kaplan ID, Chu W, Grubb W, Hannan R, Staehler M, Warner A, Louie AV The Lancet Oncology 2022 Dec 23 1508-1516
- Stereotactic Ablative Radiation for Systemic Therapy-naïve Oligometastatic Kidney Cancer
  Hannan R, Christensen M, Christie A, Garant A, Pedrosa I, Robles L, Mannala S, Wang C, Hammers H, Arafat W, Courtney K, Bowman IA, Sher D, Ahn C, Cole S, Choy H, Timmerman R, Brugarolas J European Urology Oncology 2022 Dec 5 695-703
- The Role of Stereotactic Ablative Body Radiotherapy in Renal Cell Carcinoma
  Ali M, Mooi J, Lawrentschuk N, McKay RR, Hannan R, Lo SS, Hall WA, Siva S European urology 2022 Dec 82 613-622
- Corrigendum to “The Role of Stereotactic Ablative Body Radiotherapy in Renal Cell Carcinoma” [Eur Urol 2022] (European Urology, (S030228382202468X), (10.1016/j.eururo.2022.06.017))
  Ali M, Mooi J, Lawrentschuk N, McKay RR, Hannan R, Lo SS, Hall WA, Siva S European urology 2022 Nov 82 e152
- Enrichment of “Cribriform” morphologies (intraductal and cribriform adenocarcinoma) and genomic alterations in radiorecurrent prostate cancer
  Shah RB, Palsgrove DN, Desai NB, Gagan J, Mennie A, Raj G, Hannan R Modern Pathology 2022 Oct 35 1468-1474
- The Emerging Role of Radiation Therapy in Renal Cell Carcinoma
  Christensen M, Hannan R Cancers 2022 Oct 14
- Case Report: Adaptive radiotherapy in the radiation salvage of prostate cancer
  Montalvo SK, Meng B, Lin MH, Park C, Desai NB, Hannan R, Garant A Frontiers in Oncology 2022 Aug 12
- SABR for High-Risk Prostate Cancer: A Prospective Multilevel MRI-Based Dose Escalation Trial
  Hannan R, Salamekh S, Desai NB, Garant A, Folkert MR, Costa DN, Mannala S, Ahn C, Mohamad O, Laine AM, Kim DW, Dickinson T, Raj GV, Shah RB, Wang J, Jia X, Choy H, Roehrborn CG, Lotan Y, Timmerman RD International Journal of Radiation Oncology Biology Physics 2022 Jun 113 290-301
- Phase II Trial of Sipuleucel-T and Stereotactic Ablative Body Radiation for Patients with Metastatic Castrate-Resistant Prostate Cancer
  Hannan R, Dohopolski MJ, Pop LM, Mannala S, Watumull L, Womack KB, Gao A, Garant A, Arriaga YE, Bowman I, Chung J, Wang J, Ariizumi K, Ahn C, Timmerman R, Courtney K Biomedicines 2022 Jun 10
- Stereotactic ablative radiation therapy for renal cell carcinoma with inferior vena cava tumor thrombus
  Freifeld Y, Pedrosa I, Mclaughlin M, Correa RM, Louie AV, Maldonado JA, Tang C, Kadow B, Kutikov A, Uzzo RG, Porta C, Bucknell NW, Siva S, Brugarolas J, Margulis V, Timmerman R, Hannan R Urologic Oncology: Seminars and Original Investigations 2022 Apr 40 166.e9-166.e13
- Phase II Trial of Stereotactic Ablative Radiation for Oligoprogressive Metastatic Kidney Cancer
  Hannan R, Christensen M, Hammers H, Christie A, Paulman B, Lin D, Garant A, Arafat W, Courtney K, Bowman I, Cole S, Sher D, Ahn C, Choy H, Timmerman R, Brugarolas J European Urology Oncology 2022 Apr 5 216-224
- Dose-Intensified Stereotactic Ablative Radiation for Localized Prostate Cancer
  Chen L, Gannavarapu BS, Desai NB, Folkert MR, Dohopolski M, Gao A, Ahn C, Cadeddu J, Bagrodia A, Woldu S, Raj GV, Roehrborn C, Lotan Y, Timmerman RD, Garant A, Hannan R Frontiers in Oncology 2022 Feb 12
- Outcome and Immune Correlates of a Phase II Trial of High-Dose Interleukin-2 and Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma
  Hannan R, Mohamad O, Diaz De Leon III A, Manna S, Pop LM, Zhang Z, Mannala S, Christie A, Christley S, Monson N, Ishihara D, Hsu EJ, Ahn C, Kapur P, Chen M, Arriaga YE, Courtney K, Cantarel B, Wakeland EK, Fu Y, Pedrosa I, Cowell L, Wang T, Margulis V, Choy H, Timmerman RD, Brugarolas J Clinical Cancer Research 2021 Dec 27 6716-6725
- Metastasis-directed radiation therapy after radical cystectomy for bladder cancer
  Miranda AF, Howard JM, McLaughlin M, Meng X, Clinton T, Şanli Ö, Garant A, Bagrodia A, Margulis V, Lotan Y, Hannan R, Desai N, Woldu SL Urologic Oncology: Seminars and Original Investigations 2021 Nov 39 790.e1-790.e7
- PSA-Net: Deep learning–based physician style–aware segmentation network for postoperative prostate cancer clinical target volumes
  Balagopal A, Morgan H, Dohopolski M, Timmerman R, Shan J, Heitjan DF, Liu W, Nguyen D, Hannan R, Garant A, Desai N, Jiang S Artificial Intelligence in Medicine 2021 Nov 121
- A Multi-Institutional Phase 2 Trial of High-Dose SAbR for Prostate Cancer Using Rectal Spacer
  Folkert MR, Zelefsky MJ, Hannan R, Desai NB, Lotan Y, Laine AM, Kim DW, Neufeld SH, Hornberger B, Kollmeier MA, McBride S, Ahn C, Roehrborn C, Timmerman RD International Journal of Radiation Oncology Biology Physics 2021 Sep 111 101-109
- Renal lipid metabolism abnormalities in obesity and clear cell renal cell carcinoma
  Bobulescu IA, Pop LM, Mani C, Turner K, Rivera C, Khatoon S, Kairamkonda S, Hannan R, Palle K Metabolites 2021 Sep 11
- Stereotactic Ablative Radiation Therapy for Oligoprogressive Renal Cell Carcinoma
  Schoenhals JE, Mohamad O, Christie A, Zhang Y, Li D, Singla N, Bowman I, Arafat W, Hammers H, Courtney K, Cole S, Bagrodia A, Margulis V, Desai N, Garant A, Choy H, Timmerman R, Brugarolas J, Hannan R Advances in Radiation Oncology 2021 Sep 6
- A deep learning-based framework for segmenting invisible clinical target volumes with estimated uncertainties for post-operative prostate cancer radiotherapy
  Balagopal A, Nguyen D, Morgan H, Weng Y, Dohopolski M, Lin MH, Barkousaraie AS, Gonzalez Y, Garant A, Desai N, Hannan R, Jiang S Medical Image Analysis 2021 Aug 72
- Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR) in Preclinical Models Enhances Single-Agent Immune Checkpoint Blockade
  Moore C, Hsu CC, Chen WM, Chen BP, Han C, Story M, Aguilera T, Pop LM, Hannan R, Fu YX, Saha D, Timmerman R International Journal of Radiation Oncology Biology Physics 2021 Aug 110 1306-1316
- Neoadjuvant SABR for Renal Cell Carcinoma Inferior Vena Cava Tumor Thrombus—Safety Lead-in Results of a Phase 2 Trial
  Margulis V, Freifeld Y, Pop LM, Manna S, Kapur P, Pedrosa I, Christie A, Mohamad O, Mannala S, Singla N, Wait M, Bagrodia A, Woldu SL, Gahan J, Brugarolas J, Timmerman R, Hannan R International Journal of Radiation Oncology Biology Physics 2021 Jul 110 1135-1142
- Stereotactic Ablative Radiation (SAbR) for Oligometastatic RCC
  All S, Garant A, Hannan R Seminars in Radiation Oncology 2021 Jul 31 227-234
- Hydrogel Spacer Rectal Wall Infiltration Associated With Severe Rectal Injury and Related Complications After Dose Intensified Prostate Cancer Stereotactic Ablative Radiation Therapy
  McLaughlin MF, Folkert MR, Timmerman RD, Hannan R, Garant A, Hudak SJ, Costa DN, Desai NB Advances in Radiation Oncology 2021 Jul 6
- Type I IFN activating type I dendritic cells for antitumor immunity
  Liang Y, Hannan R, Fu YX Clinical Cancer Research 2021 Jul 27 3818-3824
- Long-Term Results of a Phase 1 Dose-Escalation Trial and Subsequent Institutional Experience of Single-Fraction Stereotactic Ablative Radiation Therapy for Liver Metastases
  Folkert MR, Meyer JJ, Aguilera TA, Yokoo T, Sanford NN, Rule WG, Mansour J, Yopp A, Polanco P, Hannan R, Nedzi LA, Timmerman RD International Journal of Radiation Oncology Biology Physics 2021 Apr 109 1387-1395
- Reply to Francesco Montorsi, Alessandro Larcher, and Umberto Capitanio's Letter to the Editor re: Rohann J.M. Correa, Alexander V. Louie, Nicholas G. Zaorsky, et al. The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. Eur Urol Focus. 2019 Jun 24. pii: S2405-4569(19)30157-9. https://doi.org/10.1016/j.euf.2019.06.002. [Epub ahead of print]
  Correa RJ, Louie AV, Zaorsky NG, Lehrer EJ, Ellis R, Ponsky L, Kaplan I, Mahadevan A, Chu W, Swaminath A, Hannan R, Onishi H, Teh BS, Muacevic A, Lo SS, Staehler M, Siva S European Urology Focus 2021 Mar 7 404-405
- Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder
  Rouanne M, Bajorin DF, Hannan R, Galsky MD, Williams SB, Necchi A, Sharma P, Powles T European Urology Oncology 2020 Dec 3 728-738
- Phase II trial of hippocampal-sparing whole brain irradiation with simultaneous integrated boost for metastatic cancer
  Westover KD, Travis Mendel J, Dan T, Kumar K, Gao A, Pulipparacharuv S, Iyengar P, Nedzi L, Hannan R, Anderson J, Choe KS, Jiang W, Abdulrahman R, Rahimi A, Folkert M, Laine A, Presley C, Munro Cullum C, Choy H, Ahn C, Timmerman R Neuro-oncology 2020 Dec 22 1831-1839
- Acute interstitial nephritis, a potential predictor of response to immune checkpoint inhibitors in renal cell carcinoma
  Patel V, Elias R, Formella J, Schwartzman W, Christie A, Cai Q, Malladi V, Kapur P, Vazquez M, McKay R, Pedrosa I, Hannan R, Hammers H, Brugarolas J Journal for ImmunoTherapy of Cancer 2020 Nov 8
- Evolving Brachytherapy Boost in Prostate Cancer in the Era of Hypofractionation
  Desai NB, Garant A, Hannan R, Folkert MR International Journal of Radiation Oncology Biology Physics 2020 Nov 108 914-916
- The reintroduction of radiotherapy into the integrated management of kidney cancer
  Dohopolski M, Hannan R, Wardak Z, Hammers H, Garant A Cancer Journal 2020 Sep 26 448-459
- Type I Interferon Response in Radiation-Induced Anti-Tumor Immunity
  Zhang F, Manna S, Pop LM, Chen ZJ, Fu YX, Hannan R Seminars in Radiation Oncology 2020 Apr 30 129-138
- Tumor neoantigenicity assessment with CSiN score incorporates clonality and immunogenicity to predict immunotherapy outcomes
  Lu T, Wang S, Xu L, Zhou Q, Singla N, Gao J, Manna S, Pop L, Xie Z, Chen M, Luke JJ, Brugarolas J, Hannan R, Wang T Science Immunology 2020 Feb 5
- Addition of Iodinated Contrast to Rectal Hydrogel Spacer to Facilitate MRI-Independent Target Delineation and Treatment Planning for Prostate Cancer
  Atluri PS, Gannavarapu BS, Timmerman RD, Garant A, Hannan R, Folkert MR, Desai NB Practical Radiation Oncology 2019 Nov 9 e528-e533
- The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis
  Correa RJ, Louie AV, Zaorsky NG, Lehrer EJ, Ellis R, Ponsky L, Kaplan I, Mahadevan A, Chu W, Swaminath A, Hannan R, Onishi H, Teh BS, Muacevic A, Lo SS, Staehler M, Siva S European Urology Focus 2019 Nov 5 958-969
- Stereotactic Ablative Radiation Therapy (SAbR) Used to Defer Systemic Therapy in Oligometastatic Renal Cell Cancer
  Zhang Y, Schoenhals J, Christie A, Mohamad O, Wang C, Bowman I, Singla N, Hammers H, Courtney K, Bagrodia A, Margulis V, Desai N, Garant A, Choy H, Timmerman R, Brugarolas J, Hannan R International Journal of Radiation Oncology Biology Physics 2019 Oct 105 367-375
- PD-L1 detection using ⁸⁹Zr-atezolizumab immuno-PET in renal cell carcinoma tumorgrafts from a patient with favorable nivolumab response
  Vento J, Mulgaonkar A, Woolford L, Nham K, Christie A, Bagrodia A, De Leon AD, Hannan R, Bowman I, McKay RM, Kapur P, Hao G, Sun X, Brugarolas J Journal for ImmunoTherapy of Cancer 2019 Jun 7
- Improved Survival Outcomes for Kidney Cancer Patients With Brain Metastases
  Bowman IA, Bent A, Le T, Christie A, Wardak Z, Arriaga Y, Courtney K, Hammers H, Barnett S, Mickey B, Patel T, Whitworth T, Stojadinovic S, Hannan R, Nedzi L, Timmerman R, Brugarolas J Clinical Genitourinary Cancer 2019 Apr 17 e263-e272
- Stereotactic Radiosurgery for Multiple Brain Metastases From Renal-Cell Carcinoma
  Wardak Z, Christie A, Bowman A, Stojadinovic S, Nedzi LA, Barnett SL, Patel TR, Mickey BE, Whitworth LA, Hannan R, Brugarolas JB, Timmerman R Clinical Genitourinary Cancer 2019 Apr 17 e273-e280
- Stereotactic body radiation therapy for renal cell carcinoma with inferior vena cava thrombus-initial experience report and literature review
  Freifeld Y, Margulis V, Woldu SL, Timmerman R, Brugarolas J, Hannan R Kidney Cancer 2019 3 71-77
- Effect of chemotherapy with docetaxel with androgen suppression and radiotherapy for localized high-risk prostate cancer: The randomized phase III NRG Oncology RTOG 0521 Trial
  Rosenthal SA, Hu C, Sartor O, Gomella LG, Amin MB, Purdy J, Michalski JM, Garzotto MG, Pervez N, Balogh AG, Rodrigues GB, Souhami L, Reaume MN, Williams SG, Hannan R, Horwitz EM, Raben A, Peters CA, Feng FY, Shipley WU, Sandler HM Journal of Clinical Oncology 2019 37 1159-1168
- Fully automated organ segmentation in male pelvic CT images
  Balagopal A, Kazemifar S, Nguyen D, Lin MH, Hannan R, Owrangi A, Jiang S Physics in medicine and biology 2018 Dec 63
- Incidence and Outcomes of Delayed Targeted Therapy After Cytoreductive Nephrectomy for Metastatic Renal-Cell Carcinoma: A Nationwide Cancer Registry Study
  Woldu SL, Matulay JT, Clinton TN, Singla N, Freifeld Y, Sanli OM, Krabbe LM, Hutchinson RC, Lotan Y, Hammers H, Hannan R, Brugarolas JB, Bagrodia A, Margulis V Clinical Genitourinary Cancer 2018 Dec 16 e1221-e1235
- Reliable gene mutation prediction in clear cell renal cell carcinoma through multi-classifier multi-objective radiogenomics model
  Chen X, Zhou Z, Hannan R, Thomas K, Pedrosa I, Kapur P, Brugarolas J, Mou X, Wang J Physics in medicine and biology 2018 Oct 63
- An empirical approach leveraging tumorgrafts to dissect the tumor microenvironment in renal cell carcinoma identifies missing link to prognostic inflammatory factors
  Wang T, Lu R, Kapur P, Jaiswal BS, Hannan R, Zhang Z, Pedrosa I, Luke JJ, Zhang H, Goldstein LD, Yousuf Q, Gu YF, McKenzie T, Joyce A, Kim MS, Wang X, Luo D, Onabolu O, Stevens C, Xie Z, Chen M, Filatenkov A, Torrealba J, Luo X, Guo W, He J, Stawiski E, Modrusan Z, Durinck S, Seshagiri S, Brugarolas J Cancer discovery 2018 Sep 8 1142-1155
- Impact of Biochemical Failure After Salvage Radiation Therapy on Prostate Cancer–specific Mortality: Competition Between Age and Time to Biochemical Failure
  Jackson WC, Suresh K, Tumati V, Dess RT, Soni PD, Zhao SG, Zumsteg ZS, Hannan R, Hollenbeck BK, George A, Kaffenberger SD, Salami SS, Hearn JW, Morgan TM, Mehra R, Schipper M, Feng FY, Desai NB, Spratt DE European Urology Oncology 2018 Sep 1 276-282
- Segmentation of the prostate and organs at risk in male pelvic CT images using deep learning
  Kazemifar S, Balagopal A, Nguyen D, McGuire S, Hannan R, Jiang S, Owrangi A Biomedical Physics and Engineering Express 2018 Jul 4
- Safety and efficacy of concurrent immune checkpoint inhibitors and hypofractionated body radiotherapy
  Mohamad O, Diaz de Leon A, Schroeder S, Leiker A, Christie A, Zhang-Velten E, Trivedi L, Khan S, Desai NB, Laine A, Albuquerque K, Iyengar P, Arriaga Y, Courtney K, Gerber DE, Hammers H, Choy H, Timmerman R, Brugarolas J, Hannan R OncoImmunology 2018 Jul 7
- Natural history of ‘second’ biochemical failure after salvage radiation therapy for prostate cancer: a multi-institution study
  Tumati V, Jackson WC, Abugharib AE, Raj G, Roehrborn C, Lotan Y, Courtney KD, Bagrodia A, Gahan J, Zumsteg ZS, Folkert MR, Laine AM, Hannan R, Spratt DE, Desai NB BJU international 2018 Mar 121 365-372
- PD-L1 on host cells is essential for PD-L1 blockade–mediated tumor regression
  Tang H, Liang Y, Anders RA, Taube JM, Qiu X, Mulgaonkar A, Liu X, Harrington SM, Guo J, Xin Y, Xiong Y, Nham K, Silvers W, Hao G, Sun X, Chen M, Hannan R, Qiao J, Dong H, Peng H, Fu YX Journal of Clinical Investigation 2018 Feb 128 580-588
- Anatomical patterns of recurrence following biochemical relapse after post-prostatectomy salvage radiation therapy: a multi-institutional study
  Jackson WC, Desai NB, Abugharib AE, Tumati V, Dess RT, Lee JY, Zhao SG, Soliman M, Folkert M, Laine A, Hannan R, Zumsteg ZS, Sandler H, Hamstra DA, Montgomery JS, Miller DC, Kozminski MA, Hollenbeck BK, Hearn JW, Palapattu G, Tomlins SA, Mehra R, Morgan TM, Feng FY, Spratt DE BJU international 2017 Sep 120 351-357
- A new method to reconstruct intra-fractional prostate motion in volumetric modulated arc therapy
  Chi Y, Rezaeian NH, Shen C, Zhou Y, Lu W, Yang M, Hannan R, Jia X Physics in medicine and biology 2017 Jun 62 5509-5530
- Safety and Efficacy of Stereotactic Ablative Radiation Therapy for Renal Cell Carcinoma Extracranial Metastases
  Wang CJ, Christie A, Lin M, Jung M, Weix D, Huelsmann L, Kuhn K, Meyer JJ, Desai NB, Kim DW, Pedrosa I, Margulis V, Cadeddu JA, Sagalowsky AI, Gahan J, Laine AM, Xie X, Choy H, Brugarolas JB, Timmerman R, Hannan R International Journal of Radiation Oncology Biology Physics 2017 May 98 91-100
- Dosimetric comparison of rectal-sparing capabilities of rectal balloon vs injectable spacer gel in stereotactic body radiation therapy for prostate cancer: lessons learned from prospective trials
  Jones RT, Hassan Rezaeian N, Desai NB, Lotan Y, Jia X, Hannan R, Kim DW, Hornberger B, Dubas J, Laine AM, Zelefsky MJ, Timmerman R, Folkert MR Medical Dosimetry 2017 Feb 42 341-347
- Rationale and evidence to combine radiation therapy and immunotherapy for cancer treatment
  Ishihara D, Pop L, Takeshima T, Iyengar P, Hannan R Cancer Immunology, Immunotherapy 2016 Oct 1-18
- Key role for neutrophils in radiation-induced antitumor immune responses: Potentiation with G-CSF
  Takeshima T, Pop LM, Laine A, Iyengar P, Vitetta ES, Hannan R Proceedings of the National Academy of Sciences of the United States of America 2016 Oct 113 11300-11305
- Stereotactic body radiation therapy for low and intermediate risk prostate cancer - Results from a multi-institutional clinical trial
  Hannan R, Tumati V, Xie X, Cho LC, Kavanagh BD, Brindle J, Raben D, Nanda A, Cooley S, Kim DW, Pistenmaa D, Lotan Y, Timmerman R European Journal of Cancer 2016 May 59 142-151
- A Phase I Dose-Escalation Trial of Single-Fraction Stereotactic Radiation Therapy for Liver Metastases
  Meyer JJ, Foster RD, Lev-Cohain N, Yokoo T, Dong Y, Schwarz RE, Rule W, Tian J, Xie Y, Hannan R, Nedzi L, Solberg T, Timmerman R Annals of Surgical Oncology 2016 Jan 23 218-224
- Pretreatment biopsy analysis of DAB2IP identifies subpopulation of high-risk prostate cancer patients with worse survival following radiation therapy
  Jacobs C, Tumati V, Kapur P, Yan J, Xie XJ, Hannan R, Hsieh JT, Kim DW, Saha D Cancer Medicine 2015 Dec 4 1844-1852
- Selective Efficacy of Temsirolimus on Bone Metastases in Chromophobe Renal Cell Carcinoma
  Huelsmann L, Kim DN, Hannan R, Watumull LM, Brugarolas J Clinical Genitourinary Cancer 2015 Aug 13 e321-e323
- Stereotactic radiation therapy of renal cancer inferior vena cava tumor thrombus
  Hannan R, Margulis V, Chun SG, Cannon N, Kim DW, Abdulrahman RE, Sagalowsky AI, Pedrosa I, Choy H, Brugarolas JB, Timmerman R Cancer Biology and Therapy 2015 Jan 16 657-661
- Prostate-specific antigen decline during salvage radiation therapy following prostatectomy is associated with reduced biochemical failure
  Kabarriti R, Ohri N, Hannan R, Tishbi N, Baliga S, McGovern KP, Mourad WF, Ghavamian R, Kalnicki S, Guha C, Garg MK Practical Radiation Oncology 2014 Nov 4 409-414
- Aspirin improves outcome in high risk prostate cancer patients treated with radiation therapy
  Jacobs CD, Chun SG, Yan J, Xie X, Pistenmaa DA, Hannan R, Lotan Y, Roehrborn C, Choe KS, Kim DW Cancer Biology and Therapy 2014 Jun 15 699-706
- Combined immunotherapy with Listeria monocytogenes-based PSA vaccine and radiation therapy leads to a therapeutic response in a murine model of prostate cancer
  Hannan R, Zhang H, Wallecha A, Singh R, Liu L, Cohen P, Alfieri A, Rothman J, Guha C Cancer Immunology, Immunotherapy 2012 Dec 61 2227-2238
- Timing of postseed imaging influences rectal dose-volume parameters for cesium-131 prostate seed implants
  Yaparpalvi R, Hannan R, Landau E, Kahan N, Bodner W, Kuo HC, Minsky L, Mehta KJ, Garg MK, Kalnicki S, Guha C Brachytherapy 2012 Nov 11 489-494
- Hypofractionated whole-breast radiation therapy: Does breast size matter?
  Hannan R, Thompson RF, Chen Y, Bernstein K, Kabarriti R, Skinner W, Chen CC, Landau E, Miller E, Spierer M, Hong L, Kalnicki S International Journal of Radiation Oncology Biology Physics 2012 Nov 84 894-901
- The penetratin sequence in the anticancer PNC-28 peptide causes tumor cell necrosis rather than apoptosis of human pancreatic cancer cells
  Bowne WB, Sookraj KA, Vishnevetsky M, Adler V, Sarafraz-Yazdi E, Lou S, Koenke J, Shteyler V, Ikram K, Harding M, Bluth MH, Ng M, Brandt-Rauf PW, Hannan R, Bradu S, Zenilman ME, Michl J, Pincus MR Annals of Surgical Oncology 2008 Dec 15 3588-3600
- PNC-28, a p53-derived peptide that is cytotoxic to cancer cells, blocks pancreatic cancer cell growth in vivo
  Michl J, Scharf B, Schmidt A, Huynh C, Hannan R, Von Gizycki H, Friedman FK, Brandt-Rauf P, Fine RL, Pincus MR International Journal of Cancer 2006 Oct 119 1577-1585

Research

Investigate strategies to combine immunotherapy with SAbR (i-SAbR) for cancer treatment
Innate and adaptive immune responses generated by tumor irradiation with stereotactic ablative radiotherapy (SAbR)
Improve cancer patient treatment outcome through the design of i-SAbR clinical trials